
Physician-reviewed low testosterone education
A borderline testosterone result does not automatically mean a man has hypogonadism or needs TRT. Diagnosis depends on symptoms, repeat testing, clinical context and—when indicated—evaluation of the hypothalamic-pituitary-gonadal axis.
Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

Borderline testosterone and compensated hypogonadism describe different findings. The EAU guideline describes compensated or subclinical hypogonadism as normal testosterone with elevated LH; its clinical significance remains uncertain. A borderline-low testosterone result is a different pattern and requires confirmation and clinical interpretation.
The appropriate response is not to automatically “optimize” the testosterone number. It is to confirm the result, determine whether relevant symptoms are present, assess reversible causes and identify whether the problem is primarily testicular or related to hypothalamic/pituitary signaling.
This descriptive phrase does not establish a separate diagnosis or a need to raise testosterone to a personal “optimal” target. A value in the 300s ng/dL and nonspecific symptoms do not automatically justify TRT. Symptoms deserve assessment, including alternative causes, even when a result is within the laboratory range.
Testosterone exists on a continuum rather than switching from normal to abnormal at one biologic point. Laboratories also use different assays and reference intervals. A result near the lower limit therefore needs clinical interpretation.
The American Urological Association uses total testosterone below 300 ng/dL as a reasonable cutoff supporting the diagnosis of testosterone deficiency, but diagnosis requires compatible symptoms or signs and appropriately confirmed low levels. The Endocrine Society similarly recommends diagnosing hypogonadism only in men with symptoms/signs and unequivocally and consistently low testosterone.
Testosterone varies from day to day and can be affected by sleep, acute illness, calorie intake, medications and timing. For most men being evaluated for low testosterone, repeat morning total testosterone testing on a separate day is important before labeling the result as persistent deficiency.
A transient low value during illness or after major sleep disruption should not automatically trigger lifelong treatment.
Total testosterone can be harder to interpret when sex hormone-binding globulin (SHBG) is unusually high or low. In selected men—particularly those with borderline total testosterone or conditions affecting SHBG—an appropriately measured or calculated free testosterone can provide additional information.
Free testosterone should not be treated as a stand-alone “optimization” target. Assay quality and clinical context matter.
Sexual symptoms such as reduced libido, fewer spontaneous erections and erectile difficulties are more specific than generalized complaints such as fatigue or reduced motivation. Loss of muscle, anemia, low bone density and other findings can also be relevant.
Fatigue, brain fog, depressed mood, weight gain and poor exercise recovery are common but nonspecific. Sleep apnea, depression, thyroid disease, diabetes, obesity, medication effects and chronic illness can produce similar symptoms.
The male reproductive endocrine system is the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases GnRH, which stimulates pituitary LH and FSH. LH then stimulates Leydig cells in the testes to produce testosterone.
Primary hypogonadism originates mainly at the testes and is typically associated with an inadequate testicular response, often reflected by elevated gonadotropins. Secondary hypogonadism originates at the hypothalamic or pituitary level and may show low or inappropriately normal LH/FSH.
This distinction can change the evaluation and, in some cases, treatment strategy.
Potential contributors include obesity, type 2 diabetes and metabolic disease, obstructive sleep apnea, chronic systemic illness, opioid or glucocorticoid exposure, substantial calorie restriction and certain pituitary disorders. Aging may coexist with these factors rather than acting as the sole explanation.
Some functional causes improve when the underlying condition improves, which is why identifying them before starting TRT can matter.
When testosterone is low and LH is low or inappropriately normal, prolactin measurement may be appropriate. Markedly abnormal hormone patterns, very low testosterone, persistent hyperprolactinemia, headaches, visual symptoms or other concerning findings can warrant further pituitary evaluation.
The purpose is to avoid treating a laboratory number while missing the underlying disorder.
Not necessarily. Population testosterone levels tend to decrease with age, but chronological age alone does not define testosterone deficiency. Changes in body composition, health status, medications and comorbid disease account for part of the decline seen in older populations.
TRT should therefore not be prescribed simply because an older man's testosterone is lower than it was at age 25.
Usually not simply to raise the number. Major guidelines center treatment on men with both clinically relevant symptoms/signs and consistently low testosterone.
An asymptomatic man with a borderline result may instead need confirmation, review of reversible contributors and follow-up based on the clinical context.
TRT may be considered when testosterone deficiency has been appropriately established, relevant symptoms are present, contraindications and fertility goals have been reviewed, and the expected benefits outweigh the risks.
Potential benefits in appropriately selected hypogonadal men can include improvement in sexual symptoms and selected effects on anemia, bone density and body composition. Response varies, and treatment should be continued because it provides meaningful benefit—not merely because the laboratory value rises.
See our complete TRT guide.
When obesity, poor sleep or metabolic disease contributes to functional suppression, weight loss and treatment of underlying health problems can improve testosterone in some men. Resistance training and adequate nutrition support general health, but lifestyle changes should not be marketed as a guaranteed cure for structural testicular or pituitary disease.
Read our guide to evidence-based ways to support testosterone levels.
Evaluation commonly includes repeat testosterone measurements, symptom assessment, medical and medication history, CBC/hematocrit and investigation of the cause. LH, prolactin, SHBG/free testosterone and other testing may be appropriate depending on the initial results. Fertility goals should be discussed before exogenous testosterone is started.
PSA/prostate assessment may be appropriate based on age and risk. See our guide to hematocrit monitoring on TRT.
Low testosterone can be associated with poor health and cardiometabolic disease, but association does not prove that low testosterone itself causes cardiovascular events or that raising testosterone prevents them.
The TRAVERSE trial found testosterone therapy noninferior to placebo for major adverse cardiovascular events in men with hypogonadism and preexisting or high cardiovascular risk who met the trial's criteria. That is important safety evidence, but it is not evidence to prescribe TRT to asymptomatic men for cardiovascular prevention.
Not necessarily. In the EAU classification, compensated or subclinical hypogonadism means normal testosterone with elevated LH. That is different from overt testosterone deficiency, which requires compatible symptoms or signs and consistently low testosterone.
It may be below or near a laboratory or guideline threshold, but diagnosis still requires confirmation and clinical context. A single result should not determine treatment.
Yes, but the symptoms may or may not be caused by testosterone. SHBG/free testosterone, medications, sleep, metabolic health and other diagnoses may need consideration in selected cases.
There is no universally accepted age-specific “optimization” target that overrides proper diagnosis. Treatment targets should follow the prescribed formulation, guideline principles, symptoms and safety monitoring.
The underlying disorder may affect reproductive function, but exogenous TRT can itself suppress sperm production. Men who want current or future fertility should discuss this before treatment. See TRT and fertility.
NovaGenix can review repeat testing, symptoms, SHBG/free testosterone when appropriate, LH/prolactin, medications, health history and fertility goals before determining whether treatment is warranted. Learn about Dr. Timothy Mackey and NovaGenix Health & Wellness.
Call 561-277-8260 | Text NovaGenix | Schedule a Consultation
This article is educational and does not replace individualized medical advice, diagnosis or treatment.
Speak with NovaGenix about physician-led evaluation, testing, and treatment options in Jupiter, Florida.
Medical disclaimer: This article is for general educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Reading it does not create a physician-patient relationship. Always consult a qualified healthcare professional about your individual circumstances, and never delay seeking care because of something you read here. If you are experiencing a medical emergency, call 911. Read our full Medical Disclaimer.


609 N Hepburn avenue suite 106. Jupiter, Florida 33458
609 N Hepburn avenue suite 106. Jupiter, Florida 33458
561-277-8260
Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed